Congress Day One


Tuesday, September 7, 2021

All time in CET (EET = +1hr / BST = -1hr / EST = -6hr)


09:00 LSX Welcome

Josh Dance, SVP, LSX

Josh Dance, SVP, LSX


09:10 Keynote Presentation: How Nasdaq Nordics Markets are Driving Growth Capital for Nordic Life Sciences

Adam Kostyal, SVP, Nasdaq

Adam Kostyal, SVP, Nasdaq (moderator)


10:00 Keynote Panel: Nordic Life Sciences, Further Globally Recognised – What’s Next for the Thriving Ecosystem?

Whilst a challenging year for many reasons, 2020 felt like a step change in Nordics putting an already attractive even more firmly on the map. A number of companies passed significant private and public fundraising, clinical and company development milestones, and these positives stories continued through into 2021.

While the life sciences and healthcare industry was put ever-more under focus, in the Nordics particularly the increased capital flow and interest from international investors, pharma and other key stakeholders interested in playing their part to continue to build the maturing Nordic ecosystem was clear to see. What is next for the sector as a whole and how are these companies planning to grow, develop and internationalise further?

  • Stories of success in a time of isolation – how have companies passed key milestones while connections are harder?
  • Which models have been adopted for building companies – local and organic growth vs. more rapid global expansion?
  • What next for the Nordic regions next-wave life science leaders?

Martin Welschof, CEO, BioInvent 
Mai-Britt Zocca, CEO, IO Biotech 
Anders Martin-Löf, CFO, Oncopeptides 
Renee Aguiar-Lucander, CEO, Calliditas Therapeutics 

Martin Welschof, CEO, BioInvent 300x    Mai-Britt Zocca, CEO, IO Biotech    Anders Martin-Löf, CFO, Oncopeptides    Renee-Aguiar-Lucander--CEO--Calliditas-Therapeutics-ConvertImage-1


11:00 Presentation & Panel: Success in Investment in the Nordics and Europe – Time to Recalibrate?

While challenges, opportunities and focus areas for investment are often discussed at length, what does analysis of key wider industry trends tell us about the true dynamics of European life sciences investment, and how it’s changing? Leading Nordic and European investors discuss what learnings can investors and companies alike take from key investment metrics.

  • Do ever-increasing larger financing rounds really mean venture multiples talked about are a realistic outcome in European life sciences investments?
  • How dependent is the European life sciences venture capital dependant on well-functioning public markets? How useful is it to benchmark with the US system?
  • With increased US capital into early-stage European life sciences, will these dynamics shift?

Søren Lemonius, Managing General Partner, Sunstone Life Science Ventures 
Søren Moller, Managing Partner, Novo Seeds 
Ann-Tove Kongsnes, Investment Director, Investinor 
Moderator: Tony Proctor, Partner, Potter Clarkson

Søren Lemonius, Managing General Partner, Sunstone Life Science Ventures    Soren Moller    Ann-Tove Kongsnes, Investment Director, Investinor    Tony Proctor, Partner, Potter Clarkson


12:00 Fireside Chat: Evolving VC Strategies - Pipes and Venture in Public Equities

With strong institutional investors and a strong retail investor market, the route public for companies in the Nordics often happens earlier, which can lead to financing challenges and bottlenecks further down the line. Life science specialist VC firms in the Nordics and across Europe are increasingly breaking the mould and investing in public companies alongside private investments. Why and when would VCs allocate funds to public companies?

  • What are the drivers of this investment trend? Will we see more specialist VCs investing in public equities?
  • When do PIPEs and VCs making investments in public companies make sense, for the companies and investors?
  • Is this an untapped opportunity for the large cohort of public Nordic life sciences companies?

Ingrid Teigland Akay, Managing Partner, Hadean Ventures 

Ingrid Teigland Akay, Managing Partner, Hadean Ventures


14:00 Panel: Leading European Healthtech Innovation – Investment, Expansion and Internationalisation

While the wider European healthtech market is booming, the Nordics has become a frontrunner in digital innovation in healthcare. Nordic digital health and healthech innovation is gaining massive traction and attracting major investment. What has been key to this success and what is needed to secure the region as a globally competitive digital health innovation hub?

  • How has the Nordic region built such an innovative an internationally competitive digital ecosystem?
  • Investment trends in the healthtech – will the capital keep flowing, and what do investors need to see to fund the next generation of innovation?
  • What are the next steps for the regions leading healthtech businesses in further expansion and internationalisation?

Mats Berggren, Head of Digital Growth Opportunities and Innovation, Merck Group 
Anna-Karin Edstedt Bonamy, CEO, Doctrin 

Mats Berggren, Director, Digital Business Innovation & External Collaboration Models, M-Digital Lead, Merck KGaA    Anna-Karin Edstedt Bonamy, CEO, Doctrin 300x    


15:00 Presentation: Global Registrations – Synergies Between US and Europe Medical Device Registration

Jan Bart Hak, Head of Medical Device Department, ProPharma Group 

Jan Bart Hak, Head Medical Device Department, ProPharma Group    


16:00 Panel: Preparing for and Executing Successful Cross-Border Transactions

Life sciences is a global industry and cross-border deals are often critical for growth and internationalisation plans. Scientific, market, structural and cultural challenges are all key considerations in successful licencing, partnering or M&A deal across borders. Executives explore the optimal means of preparation of materials, readiness with relevant data and planning, as well as the pitfalls in these critical endeavours.

  • Starting dialogues and creating partnerships - what needs to be in place, anticipated and planned early to be successful?
  • What are the most common challenges and pitfalls companies face international partnerships and in executing transactions?
  • Europe, the US and beyond – building a long-term global strategy

Søren Bregenholt, CEO, Alligator Bioscience 
Magnus Corfitzen, CEO, Ascelia Pharma 
Gunilla Oswald, CEO, BioArctic 
Nathalie ter Wengel, European Lead Worldwide Business Development, Pfizer 
Moderator: Greg Benning, Managing Director, Back Bay Life Science Advisors 

Søren Bregenholt, CEO, Macrophage 300x    Magnus Corfitzen, CEO, Ascelia Pharma    Gunilla Oswald, CEO, BioArctic    Nathalie Ter Wengel 300x    Greg Benning


17:00 Video Networking Reception

 

DOWNLOAD BROCHURE